Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Feb;3(1):63-8.
doi: 10.1093/gastro/gou087. Epub 2015 Jan 6.

Optimizing the use of biological therapy in patients with inflammatory bowel disease

Alan C Moss  1
Affiliations
Review

Optimizing the use of biological therapy in patients with inflammatory bowel disease

Alan C Moss. Gastroenterol Rep (Oxf). 2015 Feb.

Abstract

Biological therapy revolutionized the treatment of inflammatory bowel disease (IBD) during the last decade. These monoclonal antibodies, which target tumor necrosis factor (TNF), integrins or IL12/23, have been approved-or are in development for-both Crohn's disease (CD) and ulcerative colitis (UC). Early use of these agents taught clinicians that induction and maintenance therapy, coupled with immunomodulator agents, reduced the immunogenicity of these agents, and led to sustained remission in many patients. More recent data has demonstrated that, through dose adjustments, optimizing serum drug levels may also provide more durable maintenance of remission, and improved mucosal healing. This review examines clinical practices that may enhance clinical outcomes from biological therapy in IBD.

Keywords: biological therapy; inflammatory bowel disease.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Strategies of biologics use in patients with inflammatory bowel disease
See this image and copyright information in PMC

References

    1. Antunes O, Filippi J, Hebuterne X, et al. Treatment algorithms in Crohn's: up, down or something else? Best Pract Res Clin Gastroenterol 2014;28:473–83. - PubMed
    1. Mandel MD, Miheller P, Mullner K, et al. Have biologics changed the natural history of Crohn's disease? Dig Dis 2014;32:351–9. - PubMed
    1. Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT Registry. Am J Gastroenterol 2014;109:212–23. - PubMed
    1. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009;104:760–7. - PubMed
    1. Vande Casteele N, Feagan BG, Gils A, et al. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives. Curr Gastroenterol Rep 2014;16:378. - PubMed

LinkOut - more resources